Current Status of CAR-T Cell Therapy in Multiple Myeloma
Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/2/4/43 |
| _version_ | 1797504170714988544 |
|---|---|
| author | Juan Luis Reguera-Ortega Estefanía García-Guerrero Jose Antonio Pérez-Simón |
| author_facet | Juan Luis Reguera-Ortega Estefanía García-Guerrero Jose Antonio Pérez-Simón |
| author_sort | Juan Luis Reguera-Ortega |
| collection | DOAJ |
| description | Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results. |
| first_indexed | 2024-03-10T04:00:51Z |
| format | Article |
| id | doaj.art-d265ed9f333140bd87ceb70041da0f8b |
| institution | Directory Open Access Journal |
| issn | 2673-6357 |
| language | English |
| last_indexed | 2024-03-10T04:00:51Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hemato |
| spelling | doaj.art-d265ed9f333140bd87ceb70041da0f8b2023-11-23T08:35:36ZengMDPI AGHemato2673-63572021-10-012466067110.3390/hemato2040043Current Status of CAR-T Cell Therapy in Multiple MyelomaJuan Luis Reguera-Ortega0Estefanía García-Guerrero1Jose Antonio Pérez-Simón2Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University Hospital Virgen del Rocio, Universidad de Sevilla, 41013 Sevilla, SpainDepartment of Hematology, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University Hospital Virgen del Rocio, Universidad de Sevilla, 41013 Sevilla, SpainDepartment of Hematology, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University Hospital Virgen del Rocio, Universidad de Sevilla, 41013 Sevilla, SpainCurrent data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results.https://www.mdpi.com/2673-6357/2/4/43myelomaCAR T-cellstarget antigen |
| spellingShingle | Juan Luis Reguera-Ortega Estefanía García-Guerrero Jose Antonio Pérez-Simón Current Status of CAR-T Cell Therapy in Multiple Myeloma Hemato myeloma CAR T-cells target antigen |
| title | Current Status of CAR-T Cell Therapy in Multiple Myeloma |
| title_full | Current Status of CAR-T Cell Therapy in Multiple Myeloma |
| title_fullStr | Current Status of CAR-T Cell Therapy in Multiple Myeloma |
| title_full_unstemmed | Current Status of CAR-T Cell Therapy in Multiple Myeloma |
| title_short | Current Status of CAR-T Cell Therapy in Multiple Myeloma |
| title_sort | current status of car t cell therapy in multiple myeloma |
| topic | myeloma CAR T-cells target antigen |
| url | https://www.mdpi.com/2673-6357/2/4/43 |
| work_keys_str_mv | AT juanluisregueraortega currentstatusofcartcelltherapyinmultiplemyeloma AT estefaniagarciaguerrero currentstatusofcartcelltherapyinmultiplemyeloma AT joseantonioperezsimon currentstatusofcartcelltherapyinmultiplemyeloma |